Patents Assigned to Immuno-Biological Laboratories Co., Ltd.
-
Patent number: 9550834Abstract: The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.Type: GrantFiled: April 17, 2015Date of Patent: January 24, 2017Assignees: THE NOGUCHI INSTITUTE, IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Takashi Shirai, Masako Mori, Masaki Kurogochi, Masahiro Tomita
-
Patent number: 9447167Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.Type: GrantFiled: March 2, 2012Date of Patent: September 20, 2016Assignee: IMMUNO-BIOLOGICAL LABORATORIES CO., LTDInventors: Satoshi Sekiguchi, Manabu Takahisa, Masahiro Tomita
-
Publication number: 20160032010Abstract: The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.Type: ApplicationFiled: April 17, 2015Publication date: February 4, 2016Applicants: THE NOGUCHI INSTITUTE, IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Takashi SHIRAI, Masako MORI, Masaki KUROGOCHI, Masahiro TOMITA
-
Publication number: 20140135483Abstract: The present invention addresses the problem of providing a novel substance capable of interfering with various functions of integrin ?4, and/or providing a novel substance capable of interfering with both integrin ?4 and integrin ?9. The present invention provides an integrin ?4 mutant peptide having one portion of the extracellular domain of human integrin ?4, and the like, and in concrete terms relates to a peptide and the like having the amino acid sequence of Sequence No. 4 through 9, and a pharmaceutical composition comprising as the active ingredient the same peptide.Type: ApplicationFiled: June 28, 2012Publication date: May 15, 2014Applicants: GENE TECHNO SCIENCE CO., LTD., IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Tsutomu Seito, Shigeyuki Kon
-
Patent number: 8710193Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.Type: GrantFiled: October 18, 2010Date of Patent: April 29, 2014Assignees: Kyoto University, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Immuno-Biological Laboratories Co., Ltd.Inventors: Kazuhiro Irie, Kazuma Murakami, Yuichi Masuda, Takahiko Shimizu, Takuji Shirasawa, Tsutomu Seito
-
Publication number: 20130345401Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.Type: ApplicationFiled: March 2, 2012Publication date: December 26, 2013Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Satoshi Sekiguchi, Manabu Takahisa, Masahiro Tomita
-
Patent number: 8329414Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.Type: GrantFiled: May 11, 2011Date of Patent: December 11, 2012Assignee: Immuno-Biological Laboratories Co., Ltd.Inventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
-
Publication number: 20120219552Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.Type: ApplicationFiled: October 18, 2010Publication date: August 30, 2012Applicants: KYOTO UNIVERSITY, IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGYInventors: Kazuhiro Irie, Kazuma Murakami, Yuichi Masuda, Takahiko Shimizu, Takuji Shirasawa, Tsutomu Seito
-
Publication number: 20120124681Abstract: Provided are a DNA fragment, a pharmaceutical composition, and the like, which can simplify the period of creating knockout animals. The DNA fragment includes: a detection sequence that codes for a detection marker other than drug resistance (preferably a visually-detectable marker); a resistance sequence that codes for a resistance marker for a drug that inhibits the proliferation of one or more species of at least prokaryotic organisms; a promoter sequence that is located upstream of the resistance sequence and functions in prokaryotic organisms; and a regulatory sequence that is located upstream of all of the above sequences and, only when inserted into a target region of the genome of at least one species of eukaryotic organism, induces the expression of a sequence located downstream. The detection sequence and the resistance sequence are arranged so as to be capable of action.Type: ApplicationFiled: July 16, 2010Publication date: May 17, 2012Applicant: Immuno-Biological Laboratories Co., Ltd.Inventors: Takayuki Shindo, Takayuki Sakurai
-
Publication number: 20110312000Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.Type: ApplicationFiled: May 11, 2011Publication date: December 22, 2011Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
-
Patent number: 7981672Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.Type: GrantFiled: September 11, 2007Date of Patent: July 19, 2011Assignee: Immuno-Biological Laboratories Co., Ltd.Inventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
-
Publication number: 20110129524Abstract: [Problems] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [Means for Solving Problems] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.Type: ApplicationFiled: May 29, 2008Publication date: June 2, 2011Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD, SAPPOROR MEDICAL UNIVERSITYInventors: Kohzoh Imai, Shigeru Sasaki, Tsutomu Seito
-
Publication number: 20100323375Abstract: Disclosed are: an agent, an apparatus and a method for the diagnosis of a disease associated with the abnormality in ?-secretase; a method for providing information for the diagnosis of a disease associated with the abnormality in ?-secretase; a method for monitoring the condition or the degree of progression of a disease associated with the abnormality in ?-secretase; and a method for determining the therapeutic effect of a therapeutic agent on a disease associated with the abnormality in ?-secretase. More specifically disclosed are: a diagnostic agent for a disease associated with the abnormality in ?-secretase, which comprises an antibody capable of recognizing a digestion product of an alcadein with ?-secretase or ?-secretase or a fragment of the antibody; and others.Type: ApplicationFiled: December 5, 2008Publication date: December 23, 2010Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATIONInventors: Masahiro Maeda, Tsutomu Seito, Toshiharu Suzuki, Saori Hata
-
Patent number: 7807777Abstract: To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein ?, Alcadein ?, or Alcadein ?; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker.Type: GrantFiled: November 1, 2004Date of Patent: October 5, 2010Assignee: Immuno-Biological Laboratories Co., Ltd.Inventors: Toshiharu Suzuki, Yoichi Araki, Naomi Miyagi, Haruyasu Yamaguchi, Masaki Nishimura, Kazuo Yamamoto
-
Publication number: 20100111939Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.Type: ApplicationFiled: September 11, 2007Publication date: May 6, 2010Applicant: Immuno-Biological Laboratories Co., LtdInventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
-
Publication number: 20080069815Abstract: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.Type: ApplicationFiled: August 8, 2007Publication date: March 20, 2008Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., Astellas Pharma Inc.Inventors: Toshimitsu UEDE, Shigeyuki Kon, Yukihiko Saeki, Yasuyuki Yokosaki, Masaki Noda, Nobuchika Yamamoto
-
Publication number: 20080025988Abstract: An antibody capable of recognizing amyloid ? while not recognizing amyloid ? precursor proteins, and a method for using the same. A monoclonal antibody characterized by being capable of recognizing the N-terminus peptide of amyloid ? while not recognizing amyloid ? precursor proteins, an amyloid ? assay kit, a therapeutic agent of Alzheimer's disease, and a method for treating Alzheimer's disease using the monoclonal antibody.Type: ApplicationFiled: September 16, 2004Publication date: January 31, 2008Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.Inventors: Haruyasu Yamaguchi, Noriaki Kinoshita, Masahiro Maeda, Yuko Horikoshi
-
Publication number: 20070274993Abstract: The invention relates to an immunocompetent cell activation inhibitor comprising an antibody against OPN or peptide fragment thereof; a therapeutic agent for diseases attributed to immunocompetent cell activation comprising this inhibitor as an active ingredient; and a method of treatment with the use of the therapeutic agent. The invention provides a medical agent capable of treating diseases attributed to immunocompetent cell activation, such as hepatopathy, asthma, arthritis, diabetes, lupus, multiple sclerosis, arteriosclerosis and lung fibrosis.Type: ApplicationFiled: May 21, 2004Publication date: November 29, 2007Applicants: Immuno-Biological LAboratories Co., Ltd., Gene Techno ScienceInventors: Shigeyuki Kon, Toshimitsu Uede, Hongyan Diao
-
Publication number: 20060002923Abstract: A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.Type: ApplicationFiled: September 25, 2002Publication date: January 5, 2006Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Toshimitsu Uede, Shigeyuki Kon, Nobuchika Yamamoto, Hirofumi Higuchi, Masaharu Torikai, Yoshiyuki Tokieda, Toshihiro Nakashima, Hiroaki Maeda